Fig 8. The small molecule GSK-J4, an inhibitor of Jmjd3 and Utx, significantly blunts IFNγ, Il-1β, and TNFα-induced chemokine gene expression in islets.

(A) A dose-response curve of Ccl2 expression in islets exposed a titration of concentrations of GSK-J4 as determined by qPCR. (B) Expression of selected chemokine and cytokine genes in islets exposed to 20μM GSK-J4 or a vehicle control (DMSO) and simultaneously untreated or treated with IFNγ, Il-1β, and TNFα (cytokine) as determined by qPCR. (C) Expression of selected genes involved in regulating β-cell function in islets exposed to 20μM GSK-J4 or a vehicle control (DMSO) and simultaneously untreated or treated with IFNγ, Il-1β, and TNFα (cytokine) as determined by qPCR. (D) Glucose-induced insulin secretion assays of islets exposed to 20μM GSK-J4 or a vehicle control (DMSO) and simultaneously untreated or treated with IFNγ, Il-1β, and TNFα (cytokine) as determined by qPCR. (E) Propidium iodide (PI) incorporation in islets exposed to 20μM GSK-J4 or a vehicle control (DMSO) and simultaneously untreated or treated with IFNγ, Il-1β, and TNFα (cytokine) as determined by qPCR. (F) Representative images of islets treated with DMSO or GSK for three and six hours respectively. PI positive cells are marked in red.